Leveraging this well‐defined mechanistic pathway and the promising therapeutic efficacy observed in AP/SAP models, targeting P‐selectin with Salvia miltiorrhiza’s bioactive compounds emerges as a compelling novel strategy for SAP‐associated microcirculatory dysfunction, laying a groundwork for subsequent validation studies. This evidence concerns the gene SELP and alkaline phosphatase measurement.